EXPLORE!

Study shows low risk of CV events with alendronate treatment in patients with hip fracture

  1322 Views

#Cardiology  #Diabetes and Endocrinology  #Orthopedics 

eMediNexus    21 May 2018

Alendronate significantly reduces the risk of cardiovascular events (incident myocardial infarction, stroke) and mortality in patients treated with the bisphosphonate following a hip fracture, says a study published online May 9, 2018 in the Journal of Bone and Mineral Research.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.